$CRTX News Article - Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimer's Disease Conference https://marketwirenews.com/news-releases/cort...22852.html
(0)
(0)
Quince Therapeutics, Inc. (QNCX) Stock Research Links